REGN-7257
- Generic Name
- REGN-7257
2D4 Monoclonal Antibody Shows Promise in Treating Systemic Lupus Erythematosus by Targeting CD132
• A novel humanized monoclonal antibody, 2D4, targeting CD132, demonstrates potential as a therapeutic agent for Systemic Lupus Erythematosus (SLE).
• 2D4 selectively inhibits IL-21 while weakly blocking IL-2, offering a more targeted approach compared to the broader CD132 inhibitor REGN7257.
• In preclinical studies, 2D4 effectively suppressed T and B cell activity, reduced autoantibody production, and improved renal function in lupus models.
• 2D4 outperformed Belimumab, a B-cell-targeted therapy, in a lupus nephritis mouse model, suggesting enhanced efficacy by targeting both T and B cells.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath